Dupilumab Improves Skin Barrier Function in Children With Atopic Dermatitis
Moderate to severe atopic dermatitis in children may see improvements in skin barrier function with dupilumab treatment, according to research published in Annals of Allergy, Asthma & Immunology. The study, conducted by researchers at National Jewish Health, found reductions in transepidermal water loss and epidermal thickness in both affected and seemingly unaffected skin areas after 16 weeks of treatment, suggesting the drug addresses underlying disease processes rather than simply managing symptoms.
Dupilumab and the Skin Barrier: A Deeper Glance
Atopic dermatitis, commonly known as eczema, is characterized by a compromised skin barrier, leading to dryness, itching and inflammation. This barrier dysfunction allows irritants and allergens to penetrate the skin, exacerbating the condition. Dupilumab, a biologic medication, targets specific proteins involved in the inflammatory pathways that drive atopic dermatitis. This latest research suggests it also has a normalizing effect on the skin’s physical barrier.
The study, led by Donald Y.M. Leung, MD, PhD, director of the food allergy and asthma program at National Jewish Health, involved 41 children aged 6 to 11 years – 23 with moderate to severe atopic dermatitis and 18 healthy volunteers. Researchers measured transepidermal water loss (TEWL), which indicates how well the skin retains moisture, and used optical coherence tomography to assess epidermal thickness. Previous research has demonstrated dupilumab’s efficacy in treating children with atopic dermatitis, and this study builds on those findings by examining its impact on skin barrier function.
Baseline measurements revealed significantly higher TEWL in both lesional (affected) and nonlesional (unaffected) skin of children with atopic dermatitis compared to healthy volunteers (55.1 g x m–2 x h–1/28 g x m–2 x h–1 vs. 14 g x m–2 x h–1). Epidermal thickness was also greater in affected skin (251.1 μm) compared to healthy skin (118.2 μm). These findings underscore the structural differences in the skin of individuals with atopic dermatitis.
Improvements Observed with Dupilumab
After 16 weeks of dupilumab treatment, researchers observed a notable reduction in TEWL in both lesional and nonlesional skin. In lesional skin, mean TEWL decreased from a baseline of 55.1 g x m–2 x h–1 to 30.3 g x m–2 x h–1. Nonlesional skin also showed improvement, with TEWL falling from 28 g x m–2 x h–1 to 22 g x m–2 x h–1. These reductions continued through week 28, with TEWL values stabilizing at 29.7 g x m–2 x h–1 in lesional skin and 18.3 g x m–2 x h–1 in nonlesional skin.
Similarly, epidermal thickness decreased in both skin types with dupilumab treatment. Lesional skin showed a reduction from 251.1 μm at baseline to 196.8 μm at week 16 and further to 160.4 μm at week 28. Nonlesional skin also exhibited a decrease, from 166.1 μm to 141.9 μm at week 16 and 142.7 μm at week 28. These changes suggest that dupilumab helps restore a more normal skin structure.
Notably, at both week 16 and week 28, TEWL and epidermal thickness in lesional and nonlesional skin were no longer significantly different from those observed in healthy skin. This suggests that dupilumab can effectively normalize skin barrier function in children with atopic dermatitis, even in areas that appear clinically unaffected.
Clinical Improvements Alongside Barrier Function
The study also tracked clinical improvements in the children with atopic dermatitis. Participants experienced significant reductions in Eczema Area and Severity Index (EASI) scores (from 34.8 to 11.3), Individual Sign Score (from 8.3 to 4.5), itch severity (from 7.6 to 3 on a numeric rating scale), skin pain (from 6.8 to 2.3), and quality of life measures (Patient-Oriented Eczema Measure from 22.3 to 9.8 and Children’s Dermatology Life Quality Index from 18 to 6.8) from baseline to week 16, and these improvements were maintained at week 28. These findings demonstrate a strong correlation between improved skin barrier function and clinical symptom relief.
Most children in the study (91.3%) experienced at least one treatment-emergent adverse event, but none were classified as serious, severe, or leading to treatment discontinuation. This suggests that dupilumab is generally well-tolerated in this pediatric population.
Implications for Atopic Dermatitis Management
These findings have important implications for the management of atopic dermatitis. Dupilumab’s ability to normalize skin barrier function suggests that it may address the underlying disease process, rather than simply suppressing symptoms. As Dr. Leung notes, “Repairing the skin barrier early in life may have important implications for preventing progression to other allergic conditions.” This is particularly relevant given the link between impaired skin barrier function and the development of other allergic diseases, known as the “atopic march.”
The study highlights the importance of considering skin barrier function as a key target in atopic dermatitis treatment. While topical emollients and moisturizers are often used to address skin dryness, dupilumab offers a more targeted approach to restoring barrier integrity by addressing the underlying inflammation. The full study, published in Annals of Allergy, Asthma & Immunology, provides detailed information on the methodology and results.
Further research is needed to determine the long-term effects of dupilumab on skin barrier function and its potential to prevent the development of other allergic conditions. However, this study provides compelling evidence that dupilumab can play a significant role in improving the lives of children with moderate to severe atopic dermatitis.
Benjamin Ungar, MD, commenting on the study, emphasized that atopic dermatitis is a complex disease involving both inflammation and epidermal barrier dysfunction. He suggests that the improvements in barrier function observed with dupilumab are likely linked to its anti-inflammatory effects. Ungar also notes that normalizing the skin barrier may aid prevent allergic sensitization and the development of the atopic march, warranting further investigation.
The process of updating clinical guidance typically involves ongoing reviews of emerging evidence, such as this study, by expert panels and regulatory bodies. These reviews may lead to revisions in treatment recommendations and guidelines for managing atopic dermatitis. Clinicians and patients should stay informed about the latest updates from organizations like the American Academy of Dermatology and the National Eczema Association.